Sheryl Jeanne Hays
University of Michigan
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Sheryl Jeanne Hays.
Journal of Steroid Biochemistry | 1985
Michael C. Tobes; Sheryl Jeanne Hays; David L. Gildersleeve; Donald M. Wieland; William H. Beierwaltes
The adrenal cortical enzyme systems, 11 beta-hydroxylase, P-450 11 beta, and the side-chain cleavage complex, P-450 scc, differ only in their cytochrome P-450s. Structural modifications of metyrapone, an inhibitor of cytochrome P-450 enzyme systems, have been made to determine the requirement for the A- or B-pyridyl ring for inhibition of P-45011 beta and P-450 scc activities. Three new analogs of metyrapone (A-phenylmetyrapone, B-phenylmetyrapone and diphenylmetyrapone) were synthesized and evaluated as inhibitors using a crude, defatted bovine adrenal cortical mitochondrial preparation. Characterization of the mitochondrial preparation demonstrated: enhancement of both activities by the addition of 15.0 microM adrenodoxin, the addition of 1% ethanol decreased both activities less than 10%, and the apparent Km of deoxycorticosterone for P-45011 beta was 6.8 microM and the apparent Km of cholesterol for P-450 scc was 21.6 microM. Inhibition of P-45011 beta and P-450 scc activities with these compounds demonstrated: the B-pyridyl ring of metyrapone is required for inhibition of both activities whereas requirement for the A-ring is less stringent, and the four metyrapone analogs were more selective inhibitors of P-45011 beta activity. These studies suggest that the A-phenyl metyrapone analog is a good candidate for further development of a selective adrenocortical radiopharmaceutical.
Bioorganic & Medicinal Chemistry Letters | 1999
Janet S. Plummer; Cuiman Cai; Sheryl Jeanne Hays; John L. Gilmore; Mark R. Emmerling; Walter Michael; Lakshmi Narasimhan; M. Desiree Watson; Kevin K. W. Wang; Rathna Nath; Lori M. Evans; Juan C. Jaen
A series of 2-sulfonyl-4H-3,1-benzoxazinones was prepared that inhibit C1r protease in vitro. Several compounds were found to be selective for C1r verses the related serine protease trypsin. Selected compounds demonstrated functional activity in a hemolysis assay.
Journal of Medicinal Chemistry | 1998
Sheryl Jeanne Hays; Bradley William Caprathe; John L. Gilmore; Nilam Amin; Mark R. Emmerling; Walter Michael; Ravi Nadimpalli; Rathna Nath; Kadee J. Raser; Daniel Stafford; Desiree Watson; Kevin K. W. Wang; Juan C. Jaen
Archive | 1997
Bradley William Caprathe; John L. Gilmore; Sheryl Jeanne Hays; Juan C. Jaen; Harry LeVine
Archive | 1996
Sheryl Jeanne Hays; Harry LeVine; Jeffrey David Scholten
Journal of Medicinal Chemistry | 1996
Ioannis Roufos; Sheryl Jeanne Hays; Roy D. Schwarz
Journal of Medicinal Chemistry | 1984
Sheryl Jeanne Hays; Michael C. Tobes; David L. Gildersleeve; Donald M. Wieland; William H. Beierwaltes
Journal of Medicinal Chemistry | 1990
Sheryl Jeanne Hays; Christopher Franklin Bigge; Perry M. Novak; James T. Drummond; Thomas P. Bobovski; Michael J. Rice; Graham Johnson; Laura J. Brahce; Linda L. Coughenour
Archive | 1996
Sheryl Jeanne Hays; Harry LeVine; Jeffery David Scholten
Journal of Labelled Compounds and Radiopharmaceuticals | 1984
Richard E. Ehrenkaufer; B. W. Agranoff; J. Bieszki; Kirk A. Frey; Sheryl Jeanne Hays; Douglas M. Jewett